Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Zimmer Biomet (ZBH)

Zimmer Biomet says Chairman Christopher Begley will retire; CEO Ivan Tornos to become Chairman

Neutral Impact 3 of 5 leadership Written later

Zimmer Biomet said Chairman Christopher Begley will retire from the Board at the 2025 Annual Meeting on May 29, 2025, under the company's mandatory director retirement policy. CEO Ivan Tornos will become Chairman on that date, and Michael Farrell will become Lead Independent Director, with the Board reducing its size to ten members. The filing reports no changes to financial results or guidance.

Key points

  • Christopher Begley, Non-Executive Chairman since August 2023, will retire at the May 29, 2025 Annual Meeting under the mandatory retirement policy.
  • Ivan Tornos, President and CEO, will become Chairman of the Board effective May 29, 2025.
  • Michael Farrell, a Board member since 2014, will become Lead Independent Director.
  • The Board will reduce its size to ten members effective upon the expiration of Mr. Begley's term.

The filing

CompanyZimmer Biomet (ZBH)
Form8-K, current report
Filed with the SECFeb 25, 2025, 4:14 PM ET
Accession number0001193125-25-035147

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.